Kinetic Analysis of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 Binding to Heparin, Heparan Sulfate, and Complement Component C3b  by Rux, Ann H. et al.
Virology 294, 324–332 (2002)Kinetic Analysis of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 Binding to Heparin,
Heparan Sulfate, and Complement Component C3b
Ann H. Rux,*,† Huan Lou,*,† John D. Lambris,‡ Harvey M. Friedman,¶ Roselyn J. Eisenberg,†,§ and Gary H. Cohen*,†,1
*Department of Microbiology, †Center for Oral Health Research, School of Dental Medicine, ‡Department of Pathology and Laboratory Medicine,
§Department of Pathobiology, School of Veterinary Medicine, and ¶Department of Medicine, School of Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania 19104
Received September 26, 2001; returned to author for revision November 10, 2001; accepted December 5, 2001
Glycoprotein C (gC) from herpes simplex virus (HSV) facilitates virus entry by attaching the virion to host cell-surface
heparan sulfate (HS). Although gC from HSV-1 (gC1) and from HSV-2 (gC2) bind to heparin, gC2 is believed to play a less
significant role than gC1 in attachment of virus to cells. This attachment step is followed by the binding of gD to one of several
cellular receptors. gC also plays an important role in immune evasion by binding to the C3b fragment of the third component
of the host complement system. Yet, although both gC1 and gC2 protect HSV against complement-mediated neutralization,
only gC on HSV-1-infected cells acts as a receptor for C3b. We used optical biosensor technology to quantitate the affinities
(KD) and the stabilities (koff) between both serotypes of gC with heparin, HS, and C3b to address three questions concerning
gC interactions. First, can differences in affinity or stability account for differences between the contributions of HSV-1 and
HSV-2 gC in attachment? Our data show that the gC2–HS complex is highly unstable (koff  0.2 s
1) compared to the gC1–HS
complex (koff  0.003 s
1), suggesting why gC2 may not play an important role in attachment of virus to cells as does gC1.
Second, does gC2 have a lower affinity for C3b than does gC1, thereby explaining the lack of C3b-receptor activity on HSV-2
infected cells? Surprisingly, gC2 had a 10-fold higher affinity for C3b compared to gC1, so this functional difference in
serotypes cannot be accounted for by affinity. Third, do differences in gC–HS and gD-receptor affinities support a model of
HSV entry in which the gC–HS interaction is of lower affinity than the gD-receptor interaction? Our biosensor results indicate
that gC has a higher affinity for HS than gD does for cellular receptors HveA (HVEM) and HveC (nectin-1). © 2002 ElsevierINTRODUCTION
Herpes simplex virus (HSV) codes for at least 11 gly-
coproteins, most of which are found on the virion enve-
lope as well as infected cell surfaces (Spear, 1993a).
Although glycoprotein C (gC) is not essential for viral
growth in vitro (Draper et al., 1984; Holland et al., 1984;
Johnson et al., 1986; Zezulak and Spear, 1984), it is rarely
absent in clinical isolates (Arvin et al., 1983; Friedman et
al., 1986; Hidaka et al., 1990) and is associated with two
important functions: entry of virus into cells via binding to
cell-surface heparan sulfate (HS) (Gerber et al., 1995;
Herold et al., 1991, 1995; Sears et al., 1991; Tal-Singer et
al., 1995) and immune evasion by HSV via binding to the
C3b fragment of the third component of complement
(Eisenberg et al., 1987; Friedman et al., 1984, 1986, 1996;
Harris et al., 1986; Hung et al., 1992; Lubinski et al., 1999,
1998; Seidel-Dugan et al., 1990), leading to down-regu-
lation of the complement cascade (Fries et al., 1986).
1 To whom correspondence and reprint requests should be ad-
dressed at the Department of Microbiology, School of Dental Medicine,© 2002 Elsevier Science (USA)
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324The entry of HSV into cells involves a series of inter-
actions between several viral glycoproteins and host cell
molecules (Spear, 1993a). Infection is initiated by the
attachment of gC and/or gB to HS glycosoaminoglycan
side chains of cell-surface proteoglycans (Herold et al.,
1991, 1994; WuDunn and Spear, 1989). In models of HSV
entry, this is considered to be a low-affinity interaction
which is then followed by the binding of gD to one of
several cellular receptors (reviewed in Spear et al., 2000),
three of which have been identified as HveA (HVEM)
(Montgomery et al., 1996) and HveC (nectin-1) (Geraghty
et al., 1998) and HS modified by a 3-O-sulfotransferase
(Shukla et al., 1999). It is generally thought that this step
is a higher affinity interaction than that between gC and
heparan sulfate (Flint et al., 2000; Roller and Rauch,
1998). Following the gD-receptor interaction, a pH-inde-
pendent fusion of the viral envelope with the cellular
membrane occurs (Wittels and Spear, 1990), facilitated
by gD, gB, and the gH–gL complex (Spear, 1993b; Turner
et al., 1998).
Although both HSV-1 and HSV-2 target HS as an at-
tachment molecule, there are type-specific differences inScience (USA)
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the way these viruses interact with host cells. Previous
studies indicated that HSV-1 mutants lacking gC1 wereiosens
on
impaired in the ability to bind cells and had reduced
specific infectivities (Herold et al., 1991). In contrast,
HSV-2 mutants lacking gC did not exhibit this phenotype
(Gerber et al., 1995; Laquerre et al., 1998). It has been
suggested that gB2 may play a more important role in
HSV-2 binding to cells than does gC2 (Gerber et al., 1995;
Herold et al., 1996). Both gC1 and gC2 bind directly to
heparin Sepharose (Herold et al., 1991; Tal-Singer et al.,
1995). We previously showed that the HS-binding do-
mains of gC1 involve, but are not limited to, the N-
terminal residues between 33 and 123 (Tal-Singer et al.,
1995). Another study indicated that residues between
143 and 150, as well as residue 247, were important for
the gC1–HS interaction (Trybala et al., 1994). Although
gC2 binds to heparin, specific binding domains on gC2
have not been localized.
Glycoprotein C modulates the host immune response
by interacting with proteins from the complement sys-
tem. Both gC1 and gC2 protect HSV against comple-
ment-mediated neutralization (Friedman et al., 1996,
2000; Gerber et al., 1995; Harris et al., 1990; Lubinski et
al., 1999; McNearney et al., 1987). In vivo, gC binding to
C3b is an important virulence factor (Lubinski et al.,
1999). Mutant HSV-1 strains that lack this ability produce
disease comparable to wild-type virus in C3 knockout
mice, but not in C3 intact mice. In the latter, 50- to
100-fold higher doses of mutant virus are required to
produce comparable disease as wild-type virus. In vitro,
gC from both serotypes binds C3b (Eisenberg et al.,
1987; Tal-Singer et al., 1995) and cells transfected with
the gene for either gC1 or gC2 bind C3b (Seidel-Dugan et
al., 1988, 1990). Interestingly, although HSV-1 infected
cells express C3b receptor activity (Friedman et al.,
1984), this is not the case for HSV-2-infected cells (Fried-
man et al., 1984, 1986). There are several possible ex-
planations for the lack of C3b receptor activity on HSV-2
infected cells: (1) Host cell membrane components may
block the receptor activity of gC2 on the infected cell
surface; (2) viral glycoproteins expressed on the cell
surface during HSV-2 infection may inhibit binding of C3b
to gC2 on the infected cell surface; or (3) the affinity of
gC2 for C3b may be lower than that of gC1.
In this study we used optical biosensor technology
(Canziani et al., 1999; Karlsson et al., 1991; Myszka, 1999)
to address three issues concerning the interactions be-
tween gC and heparin, heparan sulfate, and C3b. First,
can differences in affinity and/or stability account for the
apparent differences between gC from HSV-1 and HSV-2
in their contributions to virus binding to cells? Second,
can the lack of C3b-receptor activity on HSV-2-infected
cells be explained by a lower affinity of gC2 for C3b than
of gC1 for C3b? Third, given that both gC and gD bind to
cell-surface receptors, what are the relative affinities of
these interactions; i.e., do the differences in affinities
support the current model for HSV entry?
RESULTS AND DISCUSSION
The three forms of soluble gC used for all experiments
are shown in Fig. 1. The first set of experiments exam-
ined the binding of gC to heparin. Heparin is chemically
related to HS (Kjellen and Lindahl, 1991) and is com-
monly used as a model for HS. However, while HS is
found on cell surfaces, heparin is located intracellularly
in mast cells. Also, heparin is more highly sulfated then
HS and since the binding of heparin/HS to proteins is
generally ionic, the difference in charge between the two
may be significant. We quantitated the binding of the
three forms of gC to immobilized heparin (Fig. 2). The
solid lines represent the best global fits to a simple 1:1
binding model, using molecular masses obtained by
mass spectrometry for the gC variants (Rux et al., 1996).
The 1:1 model means that one molecule of gC binds to
one molecule of heparin to form one gC:heparin com-
plex. gC1(457t) bound to heparin with an affinity (KD) of
1.3  108 M (Table 1). Removal of residues 33–123
resulted in a 50-fold weaker affinity for heparin. This
lower affinity was primarily due to a 100-fold slower on
rate than that observed for the full ectodomain of gC.
The binding of gC2 to heparin (Fig. 2C) did not fit a 1:1
binding model; i.e., the interaction may be more complex
than a simple bimolecular reaction, and thus kinetic rate
constants cannot be calculated using this analysis. We
estimated a maximum koff of 0.02 s
1 (Table 1) (Karlsson
et al., 1991). These results indicate that the gC2–heparin
FIG. 1. Schematic diagrams of truncated forms of HSV gC1 and gC2
produced by baculovirus-infected insect cells. Both forms of gC1 were
truncated at residue 457 and gC2 was truncated at residue 426.
Additional histidine residues were added to aid in purification. The
consensus sites for N-linked oligosaccharides are shown as balloons.
In each case, the wild-type signal peptide of gC was replaced with that
of the honeybee mellitin signal. As a result of cloning, cleavage at the
mellitin signal leaves two additional amino acids on the N-terminus of
gC, aspartic acid and leucine in gC1 constructs and aspartic acid and
proline in gC2. The disulfide structure of gC1 was previously deter-
mined (Rux et al., 1996). All three forms of gC have been previously
shown to bind to heparin and C3b (Tal-Singer et al., 1995; Kostavasili et
al., 1997).
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complex is 10 times less stable than the gC1–heparin
complex. Because we could not determine an affinity
constant from the on and off rates (koff/kon  KD), we
chose to determine the KD under equilibrium conditions.
The binding of gC2 to heparin was monitored until equi-
librium was reached at each gC2 concentration. Scat-
chard analysis (Fig. 2D) gave a KD of 8  10
10 M for the
gC2–heparin complex. This is a 16-fold higher affinity
than that observed for the full ectodomain of gC1. Unlike
the interaction of gC2 with heparin, complex formation
between either gC1(457t) or gC1(33–123t) with heparin
did not reach equilibrium (within 50 min); hence Scat-
chard analysis could not be carried out. As a control,
gD1(306t) did not bind to heparin. We note that since
there is some curvature in the Scatchard plot (Fig. 2D),
the points can also fit a two component model. This
resulted in two values for KD which were not significantly
different from the single component value; thus the sin-
gle value was used to describe the interaction.
In a competition assay, 200 nM soluble heparin com-
pletely inhibited the binding of 5 nM gC1(457t) to immo-
bilized heparin (Fig. 3), suggesting that biotinylation
probably did not alter the binding sites for gC. Further-
more, the complete inhibition of binding by soluble hep-
arin suggested that the binding of gC to immobilized
heparin was specific.
In an earlier report by Williams and Straus (1997),
FIG. 2. Binding of decreasing concentrations of the indicated forms of gC to immobilized biotinylated heparin. In A and B, the flow was set to 30
L/min and five data points per second were collected, but for clarity, selected points at every 10 s are shown as open symbols. The solid lines are
the best fit to the simple bimolecular (1:1) model. In C the lines are the data for gC2(426t) where the flow was set to 2 L/min so that the contact
time could be varied from 20 min for the highest concentration to 50 min for the lowest concentration. The short arrows indicate the time points used
for the Scatchard analysis. (D) Scatchard analysis. Equilibrium binding levels (RU bound) were obtained from sensorgrams in C. C is the molar
concentration of gC2(426t). The negative inverse of the slope of the line gives a KD of 8  10
10 M. The correlation coefficient for the linear fit is 0.94.
TABLE 1
Kinetic and Affinity Values for gCt Interactions with Heparin,











gC1(457t) 130 1.6 1.3
Heparin gC1(33–123t) 1.4 0.78 55
gC2(426t) NDb 20c 0.08d
gC1(457t) 3.0 3.0 10
Heparan gC1(33–123t) 0.40 3.0 75
sulfate gC2(426t) NDb 200c 2.0d
gC1(457t) 56 16 2.8
C3b gC1(33–123t) 61 23 3.8
gC2(426t) 400 11 0.28
a 2 values from the global fits were less than 3.
b ND, not determined.
c Estimated maximum k off from ln(R 0/Rn)  k off(t n  t 0), where R 0 is
the response at time zero (t 0) of dissociation and Rn is the response at
time n (t n) (Karlsson et al., 1991).
d From Scatchard analysis.
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biosensor technology was used to investigate the inter-
action of a truncated form of gB2 binding to heparin. They
determined a KD of 7.7 10
7 M and a koff of 4 10
4 s1
for the gB2–heparin interaction. We determined a KD
value of 8.0  1010 M and a koff of 2  10
2 s1 for gC2
binding to heparin. Thus, the gB2–heparin complex has a
lower affinity but a higher stability than does the gC2–
heparin complex. Since gB2 has been suggested (Ger-
ber et al., 1995; Herold et al., 1996) to be more important
than gC2 in HSV attachment to cells, the stability of the
interaction may play a greater role than the overall affin-
ity. Perhaps gC must bind to heparan sulfate long enough
to allow gD to bind to its cell-surface receptor.
Next we examined the binding of gC1(457t), gC1(33–
123t), and gC2(426t) to immobilized biotinylated HS (Fig.
4). As expected, gD1(306t) did not bind to the HS surface.
Removal of residues 33–123 of gC1 resulted in a weaker
affinity for HS, again due to a slower on rate (Table 1). In
this case, the affinity and on rate decreased about eight-
fold when these residues were removed. Previously (Tal-
Singer et al., 1995) we looked at the ability of all three
forms of gC to bind to various cell lines (Vero, BHK, L
cells). gC1(33–123t) bound significantly less well to
cells than gC1(457t) and competed poorly with biotinyl-
ated gC1(457t) for binding, suggesting that residues 33–
123 are important for gC attachment to cells. The bio-
sensor data confirm these observations and provide
quantitative data.
gC2 bound to HS with very different kinetics when
compared with gC1 (Fig. 4C). The increased rate at
which the gC2(426t) sensorgrams reached a plateau
compared with the sensorgrams of the gC1 complexes
(Figs. 4A and 4B) indicates that the gC2–HS complex
came to equilibrium faster than the other complexes. As
FIG. 3. Soluble heparin competes with immobilized, biotinylated
heparin for binding to gC. In the top curve, 5 nM gC1(457t) alone was
injected over the heparin surface. In the lower curves, soluble heparin
at 5 or 200 nM was incubated with 5 nM gC1(457t) for 40 min and then
injected. Soluble heparin alone (200 nM) did not bind to the heparin
surface (not shown).
FIG. 4. Binding of decreasing concentrations of the indicated forms of gC to biotinylated heparan sulfate. Data for A–D are presented as described
in Fig. 1, except that all data were collected at a flow of 30 L/min. In D, the negative inverse of the slope of the line gives a KD of 2.0  10
8 M. The
correlation coefficient for the linear fit is 0.99.
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was the case for heparin, the binding of gC2 to HS did
not fit a 1:1 binding model. Scatchard analysis (Fig. 4D)
yielded an equilibrium dissociation constant of 2  108
M for the gC2–HS complex. This is a fivefold higher
affinity than that observed for the full ectodomain of gC1
(Table 1). In a competition assay, 40 M soluble HS
completely inhibited the binding of 80 nM gC1(457t) to
immobilized, biotinylated HS (Fig. 5), suggesting that the
binding of gC to immobilized HS was specific. It should
be noted that we only examined one form of heparan
sulfate. Clearly, cell and species differences in heparan
sulfate could yield different affinities. This is a subject for
further investigation.
The affinity values for gC1–HS and gC2–HS com-
plexes are in good agreement with previous results (Tal-
Singer et al., 1995), which gave an estimated affinity of
107 M for the same forms of gC binding to BHK cells
using ELISA. The estimated koff for the gC2–HS complex
was 0.2 s1, which is 2 logs faster than the koff for the
gC1–HS complex. These results indicate that the
gC2–HS complex was unstable. We speculate that dif-
ferences in stability of the respective gC–heparan sulfate
complexes may help to explain why gC1 plays a more
important role in virus attachment than gC2 (Gerber et
al., 1995).
It is of note that the calculated kon for gC1 binding to
HS was roughly 1 log slower than for gC1 binding to
heparin, resulting in a lower affinity for the HS complex.
Similar differences were seen in the affinity of gC2 for HS
compared to heparin. These results suggest that some
caution should be used when using heparin as a model
to interpret binding to HS.
Last, we looked at the binding of gC to C3b. As pre-
viously described (Sarrias et al., 2001), we attempted to
mimic the in vivo orientation of C3b by biotinylating the
protein site-specifically at the active thioester that par-
ticipates in the anchoring of C3b to cells (Law and
Dodds, 1997). The immobilization of biotinylated C3b on
the surface of a biosensor streptavidin chip was in-
tended to simulate the attachment of C3b onto the cell
surface. This oriented C3b on the chip to present a
homogenous ligand surface. Previously we used roset-
ting (Hung et al., 1992), ELISA (Kostavasili et al., 1997;
Tal-Singer et al., 1995), and C3 knockout mice (Lubinski
et al., 1999) to show that residues 33–123 of gC1 are not
part of the C3b binding domain. The biosensor data
confirm this observation and provide quantitative data
(Fig. 6). Both gC1(457t) and gC1(33–123t) bound to C3b
with similar affinities and similar kinetics (Table 1). Sur-
prisingly, gC2 bound to C3b with a 10-fold higher affinity
than did gC1. This increased affinity is accounted for by
FIG. 6. Binding of decreasing concentrations of the indicated forms
of gC to immobilized biotinylated C3b. Data are presented as described
in the legend of Fig. 1.
FIG. 5. Soluble heparan sulfate competes with immobilized, biotin-
ylated heparan sulfate for binding to gC. In the top curve, 80 nM
gC1(457t) alone was injected over the heparan sulfate surface. In the
lower curves, heparan sulfate at 800 nM or 40 M was incubated with
80 nM gC1(457t) for 40 min and then injected. Soluble heparan sulfate
alone (40 M) did not bind to the heparan sulfate surface (not shown).
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a faster rate of complex formation, kon. As a control,
gD1(306t) did not bind to the C3b chip surface. The
affinity of the gC1(457t)–C3b interaction, 2.8  108 M,
is remarkably similar to that reported for the interac-
tion between C3b and complement receptor 1 (CR1)
(Becherer et al., 1989), 2  108 M, while the affinity of
the gC2(426t)–C3b complex is 10-fold higher.
gC from HSV-1 inhibits activation of the complement
cascade by binding complement component C3b (Fried-
man et al., 1984; Fries et al., 1986; McNearney et al.,
1987) and by blocking the binding of properdin and C5 to
C3b (Hung et al., 1994; Kostavasili et al., 1997). Our data
show that the inability of gC2 on infected cells to bind to
C3b is not an affinity issue, as gC2 has a higher affinity
for C3b than does gC1. In addition, both the gC1–C3b
and the gC2–C3b complexes have similar stabilities.
Thus, the mechanism by which gC2 modulates comple-
ment-mediated neutralization remains unclear. One pos-
sibility is that gC2 on the virion binds C3b; this remains
to be evaluated. In addition, it has been suggested
(Eisenberg et al., 1987) that other cell-surface molecules
expressed during HSV-2 infection prevent C3b receptor
activity.
To determine whether there is overlap between the
binding sites for C3b and HS on gC, two concentrations
of HS were incubated with 50 nM gC1(457t) for 40 min
prior to injection over the C3b chip surface (Fig. 7). HS at
a concentration of 50 M almost completely inhibited the
binding of gC to C3b. Therefore, there may be overlap
between C3b and HS binding sites on gC. Our inhibition
data are consistent with a previous study that showed
that heparin inhibited the binding of C3b-coated erythro-
cytes to HSV-1-infected Vero cells (Huemer et al., 1992).
Trybala et al. (1994) identified residues between 143 and
150 and residue 247 as part of the HS-binding domain on
gC1. We previously identified four noncontiguous do-
mains (Regions I–IV) in the central portion of gC1 that
bind to C3b (Hung et al., 1992). In this model, Region I is
adjacent to residues 143–150 and Region IV contains
residue 247. However, we also determined that the HS
binding domains on gC1 include residues 33–123 (Tal-
Singer et al., 1995), which are not part of the C3b binding
domains. Taken together, these data suggest that the HS
and C3b binding sites on gC1 may overlap but are not
identical. Alternatively, HS may alter the conformation
of gC such that the C3b binding site is no longer acces-
sible.
We can also compare the binding constants for the
gC–HS complex with that of the gC–C3b complex for
each serotype of gC (Table 1). gC1(457t) has a roughly
threefold higher affinity for C3b than for HS, while
gC2(426t) has a sevenfold higher affinity for C3b than for
HS. In each case, changes in both the rate of complex
formation (kon) and the complex stability (koff) contribute
to the higher affinities. The functional implications of
these differences remain to be explored.
To our knowledge, this is the first report of affinity and
kinetic values for gC binding to heparin, HS, and C3b.
Previously, we used optical biosensor technology to de-
termine the affinity of gD for cellular receptors HveA (Rux
et al., 1998; Willis et al., 1998) and HveC (Krummenacher
et al., 1999; Whitbeck et al., 1999). Therefore, it is now
possible to quantitatively compare the interaction of gC
with HS to that of gD with receptors. The ectodomain of
gD, gD1(306t), bound to both HveA and HveC with a KD of
30  107 M. The data in this paper show that the affinity
of the gC1–HS complex is 30-fold higher (1  107 M)
than the affinity of gD for any of its receptors. This trend
in affinities was surprising to us, in light of the prevailing
idea in the HSV field, which is that gC and/or gB bind to
HS proteoglycans with a low affinity that allows virus to
attach loosely to cells (grazing over the surface) and
position virion gD in close enough proximity to interact
with higher affinity to a specific cellular receptor (Flint et
al., 2000; Roller and Rauch, 1998). Our data suggest that
the opposite may in fact be the case, i.e., that the gC–HS
interaction has a higher affinity than the gD–receptor
interaction. Thus, we propose that a more appropriate
model for the initial steps in HSV entry into cells should
include the following: (1) HSV gC attaches tightly to the
cell via abundant heparan sulfate proteoglycans; and (2)
if a less abundant cellular receptor for virion gD is
nearby, the entry process can continue. If no gD receptor
is available near the site where initial attachment occurs,
then this particular virion would remain attached to the
surface and be unable to carry out the later steps of
entry. The caveat here is the assumption that the inter-
actions between soluble molecules mimic those be-
tween virion and cell-surface molecules. Even if the ab-
solute affinities are different, we propose that the binding
of virion gC to heparan sulfate is tighter than the binding
of virion gD to cellular receptors.
FIG. 7. Competitive inhibition of gC1(457t) binding to immobilized
C3b by soluble heparan sulfate. In the top curve, 50 nM gC1(457t) alone
was injected over the HS surface. In the lower curves, soluble HS at 5
or 50 M was incubated with 50 nM gC1(457t) for 40 min and then
injected. Soluble HS alone (50 M) did not bind to the C3b surface (not
shown).
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MATERIALS AND METHODS
Construction, production, and purification of gC
baculovirus recombinants
The construction, production, and purification of gC1(457t),
gC1(33–123t), and gC2(426t) were described previously
(Tal-Singer et al., 1995). All recombinants were produced
in a baculovirus expression system and truncated (gCt)
prior to the transmembrane region. gC1(457t) contains
the ectodomain of gC1, being truncated at residue 457.
gC1(33–123t) is identical to gC1(457t) except that it
lacks amino acids 33–123. gC2(426t) is truncated at res-
idue 426. We previously showed that these baculovirus-
expressed proteins are similar in conformation to full-
length gC isolated from HSV-infected cells and that all
bind to C3b (Tal-Singer et al., 1995). Purified protein was
used in all experiments.
Biotinylation of heparin, heparan sulfate, and C3
Heparin from bovine kidney (Sigma) or heparan sulfate
from porcine intestinal mucosa (Seikagaku) were dis-
solved in PBS and biotinylated at primary amino groups
for 1 h at room temperature with a molar excess of
sulfo-N-hydroxysuccinimide-biotin (Pierce) (Williams and
Straus, 1997). Excess biotin was removed using a 100-
fold buffer exchange via ultrafiltration (3000 MW cutoff).
The production of site-specifically biotinylated C3b
from human serum was previously described (Sarrias et
al., 2001). Briefly, the thioester bond of native C3 from
human serum was hydrolyzed by methylamine and the
product was biotinylated using EZ-Link PEO-maleimide-
activated biotin (Pierce, Rockford, IL). Upon removal of
free biotin, C3 was cleaved with trypsin to produce bio-
tinylated C3b, which was purified by ion-exchange chro-
matography as previously described (Sarrias et al., 2001).
Biotinylated-C3b, -heparin, and -heparan sulfate were
aliquoted and stored at 80°C.
Optical biosensor analysis
All surface plasmon resonance (SPR) experiments
were carried out on a BIACORE X (Biacore, AB) at 25°C
as previously described (Krummenacher et al., 1999; Rux
et al., 1998; Willis et al., 1998). The running buffer was
HBS (10 mM HEPES, 150 mM NaCl, pH 7.4) containing
0.05% P-20 (surfactant). The SA sensor chip (Biacore)
was used for all experiments and consisted of strepta-
vidin precoupled to all cells. The streptavidin surface
was preconditioned with four 1-min pulses of 50 mM
NaOH in 1 M NaCl before addition of the biotinylated
species. In each case, the biotinylated ligand was cou-
pled to flow cell 2 (Fc2). Flow cell 1 was left as a
streptavidin control to compensate for nonspecific bind-
ing and for changes in refractive index upon addition of
sample. All data were corrected by subtracting the data
on Fc1 from that on Fc2. In all cases, the nonspecific
binding was less than 5% of the total binding. Binding
rates were unaffected by flow rate, demonstrating that
these gC–ligand interactions were not limited by diffu-
sion and thus the rates determined are truly reflective of
the gC–ligand interaction (data not shown) (Morton and
Myszka, 1998).
(1) Binding of gC to biotinylated heparin or heparan
sulfate
Biotinylated heparin or biotinylated heparan sulfate
was diluted in running buffer to approximately 25 g/mL
and flowed over preconditioned flow cell 2 at 5 L/min
until approximately 70 resonance units (RU) were immo-
bilized. To characterize the binding of gC variants to
heparin or heparan sulfate, the flow path was set to
include both flow cells, the flow rate was set to 30
L/min, and the data collection rate was set to high (5
Hz). Each gC sample was injected over a 3-min period to
follow association. Then the sample was replaced with
buffer and the dissociation phase followed for 3 min. For
equilibrium experiments with gC2–heparin the flow rate
was set to 2 L/min to allow for longer contact times.
The chip surface was regenerated with 0.2 M Na2CO3,
pH 9.0, to remove any residually bound gC.
(2) Binding of gC to biotinylated C3b
Biotinylated C3b was diluted in running buffer to a final
concentration of 10 g/mL and flowed over flow cell 2 at
5 L/min until approximately 700 RU were immobilized.
Binding of serial dilutions of gC to C3b and regeneration
of the C3b surface were carried out as above.
Data analysis
SPR data were analyzed using BIAevaluation software,
version 3.0, which employs global fitting. Model curve
fitting was done using a 1:1 Langmuir interaction with
drifting baseline. For the interaction of gC2(426t) with
heparin or heparan sulfate, Scatchard analyses were
performed to determine the affinities and a maximum koff
was estimated by using the equation ln(R0/Rn)  koff(tn 
t0), where R0 is the response at time zero (t0) of dissoci-
ation and Rn is the response at time n (tn) (Karlsson et al.,
1991).
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